Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.

about

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.

Item

http://www.wikidata.org/entity/Q55383790

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Migalastat improves diarrhea i ...... from the phase 3 FACETS trial.

@en

Migalastat improves diarrhea i ...... from the phase 3 FACETS trial.

@nl

type

Item

label

Migalastat improves diarrhea i ...... from the phase 3 FACETS trial.

@en

Migalastat improves diarrhea i ...... from the phase 3 FACETS trial.

@nl

prefLabel

Migalastat improves diarrhea i ...... from the phase 3 FACETS trial.

@en

Migalastat improves diarrhea i ...... from the phase 3 FACETS trial.

@nl

P1476

Migalastat improves diarrhea i ...... from the phase 3 FACETS trial.

@en

P2093

Ana Jovanovic

http://www.w3.org/2001/XMLSchema#string

Andrew Mulberg

http://www.w3.org/2001/XMLSchema#string

Daniel G Bichet

http://www.w3.org/2001/XMLSchema#string

Derralynn A Hughes

http://www.w3.org/2001/XMLSchema#string

Fred Holdbrook

http://www.w3.org/2001/XMLSchema#string

J Charles Jennette

http://www.w3.org/2001/XMLSchema#string

Jay A Barth

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Castelli

http://www.w3.org/2001/XMLSchema#string

Kathleen Nicholls

http://www.w3.org/2001/XMLSchema#string

Laura Barisoni

http://www.w3.org/2001/XMLSchema#string

P2860

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

Neurological complications of Anderson-Fabry disease.

Gastrointestinal involvement in Fabry disease. So important, yet often neglected.

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.

Prevalence of lysosomal storage disorders.

Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study

P2888

s13023-018-0813-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13023-018-0813-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103668955

http://www.w3.org/2001/XMLSchema#string

P698

29703262

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

biomarker

P932

5923014

http://www.w3.org/2001/XMLSchema#string